Market Overview

Immuno-oncology Report Bundle 2018: Inhibitory & Stimulatory Immunomodulators

Share:

Immuno-oncology Report Bundle 2018: Inhibitory & Stimulatory Immunomodulators

PR Newswire

DUBLIN, July 31, 2018 /PRNewswire/ --

The "Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).

Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:


Negative Immune Checkpoints

  • PD-1 (programmed cell death 1)
  • PD-L1 (programmed cell death ligand 1 (PD-L1)
  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
  • LAG-3 (Lymphocyte Activation Gene 3; CD223)
  • TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
  • TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)
  • B7-H3 (CD276)
  • Others (VISTA: V-region Ig-containing Suppressor of T-cell Activation; BTLA: B- and T-Lymphocyte Attenuator; GARP: Glycoprotein A Repetitions Predominant; PVRIG; B7-H4)

Stimulatory Immune Checkpoints

  • CD40 (TNFSFR5)
  • GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
  • OX40 (CD134; TNFSFR4)
  • 4-1BB (CD137; TNFSFR9)
  • CD27 (TNFSFR7)
  • ICOS (Inducible Co-Stimulator)

Immunosuppressive tumor microenvironment

  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4) & othe novel chemokines/receptors
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 - SIRP (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase)

More than 190 unique molecules (many antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. This number has more than doubled since December 2016.

The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of information

Reports Included

Report 1: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

1a) PD-1 Receptor Antagonists:

  • Approved and Marketed PD-1 Antagonists
  • Specific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
  • Specific PD-1 Antagonists in Non- or Pre-Clinical Development
  • Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development

1b) PD-L1 Inhibitors:

  • Approved and Marketed PD-L1 Inhibitors
  • Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
  • Specific PD-L1 Inhibitors in Non- and Preclinical Development
  • Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development

2) Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines

Report 2: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

1a) CTLA-4 Receptor Antagonists:

  • Selective CTLA-4 Antagonist in Clinical Development in Regulated Markets
  • Selective CTLA-4 Antagonist in Clinical Development in Less Regulated Markets
  • Bispecific CTLA-4 Antagonist in Clinical Development
  • Selective or Bispecific CTLA-4 Antagonists in Non-Clinical Development
  • Selective or Bispecific CTLA-4 Antagonist in Preclinical R&D

1b) LAG-3 Antagonists:

  • Relatlimab Pipeline
  • Selective LAG-3 Antagonists in Clinical Development
  • Bispecific LAG-3 Antagonists in Clinical Development
  • LAG-3 Antagonists in Non-Clinical Development
  • LAG-3 Antagonists in Preclinical R&D

1c) TIM-3 Antagonists:

  • Selective and Bispecific TIM-3 Antagonists in Clinical Development
  • Selective and Bispecific TIM-3 Antagonists in Non-Clinical Development
  • TIM-3 Antagonists in Preclinical R&D

1d) TIGIT Antagonists:

  • TIGIT Antagonists in Clinical Development
  • TIGIT Antagonists in Non-Clinical Development
  • TIGIT Antagonists in Preclinical R&D

1e) Other Inhibitors of Negative Immune Checkpoints

  • B7-H3 Targeted Immune Checkpoint Inhibitors
  • Inhibitors of Other Immune Checkpoints

2) Corporate Inhibitors of Negative Immune Checkpoints R&D Pipelines

Report 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators

  • CD40 Agonists
  • GITR Agonists
  • OX40 Agonists
  • 4-1BB (CD137) Agonists
  • CD27 Agonists1f) ICOS Agonists
  • Other Immune Checkpoint Activators

2) Corporate Immune Checkpoint Activator R&D Pipelines

Report 4: Tumor Microenvironment Modulation via IDO, TGF-, CXCR4, CSF-1R, CD47-SIRP, adenosine pathway & STING 2018

1a) IDO & TDO Inhibitors

  • First-Generation Selective IDO-1 Inhibitors
  • Novel Selective IDO-1 Inhibitors
  • Dual IDO/TDO Inhibitors
  • Selective TDO Inhibitors
  • Other Approaches for IDO or TDO Inhibition

1b) TGF-beta Inhibitors

  • Indirect TGF-beta Inhibition
  • Selective TGF-beta1 Inhibitors
  • Selective TGF-beta2 Inhibitors
  • Dual or Triple TGF-beta Inhibitors
  • Bispecific TGF-beta Inhibition

1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

  • CXCR4 Antagonists
  • CXCL12 / SDF-1 Inhibitors

1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

  • Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
  • Other Interleukin Inhibitors
  • CCR2/CCR5 Antagonists
  • CCR4 Antagonists

1e) CSF-1R Antagonists & CSF-1 Inhibitors

  • Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
  • Selective CSF-1R Antagonists and CSF-1 Inhibitors

1f) CD47 Antagonists & SIRPalpha Inhibitors

  • CD47 Antagonists
  • SIRP Inhibitors
  • Bispecific CD47 Antagonists

1g) Adenosine Pathway Modulation

  • Selective Adenosine A2A Receptor Antagonists
  • Selective Adenosine A2B Receptor Antagonists
  • Dual Adenosine A2 Receptor Antagonists
  • CD73 Ectoenzyme Inhibitors
  • CD39 Ectoenzyme Inhibitors
  • Other Approaches

1h) STING Agonists

2) Corporate Tumor Microenvironment Modulator R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/6b9cn3/immunooncology?w=5

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 




Cision View original content:http://www.prnewswire.com/news-releases/immuno-oncology-report-bundle-2018-inhibitory--stimulatory-immunomodulators-300689181.html

SOURCE Research and Markets

View Comments and Join the Discussion!